Xarelto tablets film-coated

Land: Armenia

Språk: engelsk

Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiv ingrediens:

rivaroxaban

Tilgjengelig fra:

Bayer AG

ATC-kode:

B01AF01

INN (International Name):

rivaroxaban

Dosering :

15mg

Legemiddelform:

tablets film-coated

Enheter i pakken:

(28/2x14/), in blister

Resept typen:

Prescription

Autorisasjon status:

Registered

Autorisasjon dato:

2020-02-07

Preparatomtale

1
RESTRICTED
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
RESTRICTED
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Xarelto 15 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 15 mg rivaroxaban.
Excipient with known effect
Each film-coated tablet contains 24.13 mg lactose (as monohydrate),
see section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature)
marked with the BAYER-
cross on one side and “15” and a triangle on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation with
one or more risk factors, such as congestive heart failure,
hypertension, age ≥ 75 years, diabetes
mellitus, prior stroke or transient ischaemic attack.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),
and prevention of recurrent
DVT and PE in adults. (See section 4.4 for haemodynamically unstable
PE patients.)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Prevention of stroke and systemic embolism _
The recommended dose is 20 mg once daily, which is also the
recommended maximum dose.
Therapy with Xarelto should be continued long term provided the
benefit of prevention of stroke and
systemic embolism outweighs the risk of bleeding (see section 4.4).
If a dose is missed the patient should take Xarelto immediately and
continue on the following day with
the once daily intake as recommended. The dose should not be doubled
within the same day to make
up for a missed dose.
3
RESTRICTED
_Treatment of DVT, treatment of PE and prevention of recurrent DVT and
PE _
The recommended dose for the initial